Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM: Exemestane vs Tamoxifen followed by Exemestane in Early Breast Cancer
NCT00036270Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2001
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Disease Free Survival at 5 years. Started Aug 2001; status: completed.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00036270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036270.